January 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Dec 25, 2025, 16:33

Jack Shuang Hou on FDA Approval of Aqvesme: First Oral Therapy for Thalassemia Anemia

Jack Shuang Hou, Scientific Director at Jtests, shared on LinkedIn:

”FDA Approves First Oral Therapy to Agios Pharmaceuticals’ mitapivat (Aqvesme) for Thalassemia Anemia — A True Milestone Moment

The FDA has approved mitapivat (Aqvesme) from Agios Pharmaceuticals, marking the first-ever oral therapy for adults with α- or β-thalassemia, across both transfusion-dependent and non-transfusion-dependent disease.

This is a landmark advance for a community that has waited decades for meaningful innovation.

Here’s why this approval truly matters

First-in-Class, Disease-Modifying Oral Option
Mitapivat is the first approved treatment addressing the underlying red blood cell dysfunction in thalassemia—not just managing symptoms. Until now, many patients relied solely on lifelong transfusions or had no pharmacologic options at all.
Strong Phase 3 Evidence (ENERGIZE and ENERGIZE-T)

Data from ENERGIZE and ENERGIZE-T (452 patients globally) showed:

Significant hemoglobin improvement
Reduced fatigue
Meaningful reduction in transfusion burden, with some patients achieving transfusion independence

As noted by Hanny Al-Samkari (Mass General Brigham), these trials directly addressed the most burdensome aspects of the disease.

3. Safety Matters: Boxed Warning and REMS

The approval includes a boxed warning for hepatocellular injury, requiring a REMS program with:

Certified prescribers and pharmacies
Liver function monitoring every 4 weeks for the first 6 months

This highlights the FDA’s careful balance between access and safety for rare-disease therapies.

4. Commercial Readiness
Agios plans to make Aqvesme available in the U.S. by late January 2026, setting the stage for rapid real-world impact.

5. A Century in the Making
As Ralph Colasanti of the Cooley’s Anemia Foundation noted, this approval comes nearly 100 years after thalassemia was first described—a powerful reminder of how long patients have waited for progress.

My Takeaway
This is more than a drug approval—it’s a paradigm shift.
Oral, disease-modifying therapy for both TD and NTDT thalassemia fundamentally changes long-term care, quality of life, and health system burden.
It also reinforces how precision metabolic targeting can unlock breakthroughs in rare hematologic diseases.

Aqvesme sets a new bar—not just for thalassemia, but for what patients should expect from modern rare-disease drug development.”

Read the full announcement here.

Jack Shuang Hou on FDA Approval of Aqvesme: First Oral Therapy for Thalassemia Anemia